Successes in the UAE and KSA, other emerging markets demonstrate AIG’s innovative global leadership in the live social industry
DUBAI, UNITED ARAB EMIRATES.-Monday 28 February 2022 [ AETOS Wire ]
Asia
Innovations Group’s (AIG) flagship app Uplive has been ranked as the
world’s third fastest-growing social app by third-party analytical
platforms AppAnnie and Sensor Tower.
The
global rankings, which come hot on the heels of the app’s unveiling of
its first-ever Television Commercial for the Middle East region, which
aired on Rotana, and a raft of GCC-centric features, exemplified AIG’s
leadership in the global live social industry, and are results of AIG's
continued focus to serve the emerging markets.
In 2021, AIG’s
flagship live streaming app Uplive and dating apps Lamour and Cute U
clinched top places in global app rankings based on downloads and
consumer spending.
Uplive, the largest independent global video
social entertainment platform, has consistently risen to become the top
consumer spend app in APAC in 2021, according to App Annie. Uplive has
also emerged as the fastest-growing live streaming app globally as
measured by year-on-year growth in downloads, according to Sensor Tower.
Since
the unveiling of the GCC-wide campaign, Uplive has attracted a large
number of GCC-based live streamers, which has, in turn, boosted its
Middle East subscriber base significantly with KSA and the UAE
accounting for the lion’s share.
According to AIG, the leading
live social company with 520 million registered users located in over
150 regions worldwide, Uplive’s growth in users was matched by
significant revenue growth, where Uplive moved to the third
fastest-growing Android app globally.
“We are pleased to be
ranked as the third fastest-growing app in the world – an achievement
that has been made possible by our ever-growing global fanbase. The
app’s popularity is fully driven by the consumer-centric features and
value it delivers to all its users. Through innovation, we have been
able to design a value-driven platform that not only delivers real,
customised entertainment to users but also provides a safe space for
young entertainers to showcase their talents and earn while doing what
they love,” said Andy Tian, chief executive officer, AIG.
“AIG is
dedicated to providing an unbeatable user experience across our
products, which our tremendous growth in 2021 reflects. We are proud of
our leadership in the global app industry and our supremacy in emerging
markets, including the GCC and the talent-rich UAE in particular. Our
significant growth in 2021 is just the beginning; we look forward to
introducing truly ground-breaking features in the upcoming year,” noted
Andy.
The success of AIG products also reflects the global growth
of the dating app and live streaming industries. App Annie reports that
time spent on live-streaming apps increased by 900% since 2018, while
time spent on dating apps increased by 95%. In the GCC alone, time spent
on Uplive has significantly increased over the last few months
signaling a growing appetite for Arabic content – an important
demographic that had been underserved by other players.
As the
foremost company producing live social products, AIG is strongly
positioned as an industry leader in live streaming and dating apps. By
placing a priority on emerging markets such as the Middle East and
diversifying their offerings for local markets, AIG has tapped hitherto
neglected but talent-rich markets to serve a truly global user base.
About Asia Innovations Group
Asia
Innovations Group is a leading live social company with 520 million
registered users located in over 150 regions worldwide. It has built a
comprehensive and diverse portfolio as it seeks to achieve its mission
of enriching people's lives worldwide through innovative and enjoyable
live social products, which foster meaningful human connections. In
addition to Uplive, which allows video social hosts to broadcast to the
world, AIG owns CuteU and Lamour, the top dating app in global emerging
markets. It includes operations in 18 offices around the globe that
integrate local live social knowledge to foster individual market
development and penetration. Focusing on major emerging markets, AIG
leverages its track record of innovation, cutting-edge technology, a
scalable global infrastructure, and global insights with local expertise
to deliver user and shareholder value based on the most exciting growth
opportunities in the live social marketplace.
Contacts
Melwyn Abraham - melwyn@matrixdubai.com
Permalink : https://www.aetoswire.com/news/aigrsquos-uplive-ranked-among-fastest-growing-apps-globallynbsp/en
Tuesday, March 1, 2022
AIG’s Uplive ranked among fastest-growing apps globally
ZAPI GROUP Launches Inaugural Conference, The Future of Electrification 2022
Event will highlight global electrification efforts and showcase keynote speakers in the industrial electrification space
POVIGLIO, Italy-Monday 28 February 2022 [ AETOS Wire ]
(BUSINESS WIRE) -- ZAPI GROUP, a global leader in electrification, is announcing the launch of “The Future of Electrification” conference. The event is the company’s first educational virtual event and will take place on April 5 - 7, 2022.
The Future of Electrification will bring together design and R&D engineers, product managers, academics and executives to learn and discuss market trends, emerging technologies, best practices, practical challenges, and opportunities of industrial electrification.
The event aims to facilitate connections, increase collaboration, and propel the worldwide electrification effort through technical and forward-looking discussions, presentations and networking events.
“ZAPI GROUP is a pioneer in the design and manufacture of electrification components and is advancing global movement towards electrifying industrial applications to help customers meet evolving requirements,” said Claes Avasjo, Executive Director, ZAPI GROUP. “We are excited about the inaugural Future of Electrification 2022 - an event for our customers, partners, and electrification innovators to come together to imagine and create applications that facilitate the transition to an all-electric future.”
The following conference keynote speakers, representing leaders and innovators in this field, have been confirmed – with more to follow:
Saul Griffith, Engineer, inventor, entrepreneur, MacArthur “genius grant” recipient and author of “Electrify - An Optimist’s Playbook for our Clean Energy Future.”
Jonathan Dawley, President & CEO of KION North America Corporation
Tom Nguyen, VP Business Development, Inventus Power
Matt Zaremba, Director, Product Strategy, TSV (EZGO)
Dr. Nicola Tomatis, CEO of BlueBotics
The curated event will offer a combination of pre-recorded and live presentations, Q&A sessions, panel discussions and virtual networking activities. All presentations will also be available to registrants after the event. There is no cost to attend this inaugural event, but registration is required through the Accelevents virtual events platform.
To register for the Future of Electrification 2022, visit: www.futureofelectrification.org
About ZAPI GROUP
ZAPI GROUP is engineering the transition to an all-electric future with a highly integrated product portfolio including motion controllers, electric motors, high-frequency battery chargers and autonomous navigation software for application in full electric and hybrid vehicles.
As a global electrification leader with deep systems experience, leading innovations and an obsession with driving customers’ success, ZAPI GROUP now counts more than 1500 employees worldwide with total annual revenue of more than 600 million US dollars. For more information, visit www.zapigroup.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005214/en/
Contacts
Media Contact
AnnMarie Carson, Communiqué PR
Phone: (206) 282-4923
ZapiGroupPR@communiquepr.com
ويمايد تكشف النقاب عن لعبة تجميع مكافآت جديدة ضمن لعبة إم آي آر 4
أعلنت الشركة عن طرح لعبة تجميع شخصيات الرموز غير القابلة للاستبدال، MIRAGE.
سيول، كوريا الجنوبية -الاثنين 28 فبراير 2022 [ ايتوس واير ]
(بزنيس واير) - كشفت "ويمايد" النقاب عن لعبة جديدة لتجميع شخصيات الرموز غير القابلة للاستبدال، MIRAGE، موسعة بذلك العوالم المتعددة للعبتها "إم آي آر 4" القتالية المتميزة لتقمص الأدوار متعددة اللاعبين على الإنترنت الشهيرة والتي تحظى بترحيب واسع.
هذا وتعدّ MIRAGE لعبة ثورية لتجميع المكافآت تجري أحداثها في عالم موازٍ منفصل عن لعبة "إم آي آر 4"، إنما لا تزال مترابطة مع المنظومة المدعومة من عملات Draco الرقمية. يستطيع اللاعبون إستخدام شخصيات الرموز غير القابلة للاستبدال خاصتهم من لعبة "إم آي آر 4" في عالم MIRAGE القائم على شبكة الإنترنت من أجل استخراج معادن "دارك ستيل" وSeptaria من العقد المتعددة في الوادي المخبأ Hidden Valley. وتقدم MIRAGE نهجاً جديداً لتجميع المكافآت، يستند إلى أساسيات الإدارة الكلية من خلال تطبيق عناصر اللعبة على شخصيات الرموز غير القابلة للاستبدال باعتبارها أصولاً قابلة للعب، وبالتالي توسيع نطاق النشاط الاقتصادي ضمن منظومة لعبة "إم آي آر 4".
سيحتاج اللاعبون إلى حساب محفظة "ويميكس واليت" (WEMIX Wallet) للمشاركة في اللعبة، كما يتعين عليهم إستخدام واحدة أو أكثر من شخصيات الرموز غير القابلة للاستبدال ضمن قائمةroster MIRAGE خاصتهم. أما الأشخاص الذين لا يملكون حساباً في لعبة "إم آي آر 4"، فيمكنهم المشاركة من خلال تسجيل الدخول في محفظة "ويميكس واليت".
تجدر الإشارة إلى أن الدخول إلى الوادي المخبأHidden Valley في لعبة MIRAGE يتطلب رمز Vigor، والذي يمكن الحصول عليه مقابل Hydra، وهي الرموز الخاصة بالألعاب في لعبة "إم آي آر 4". وهناك حد أقصى لعدد الشخصيات التي يمكن تجميعها في كل وادي مخبأ، وعندما يمتلىء الوادي المخبأ، يمكن للاعبين آخرين محاولة ’مهاجمة‘ أضعف شخصية من الرموز غير القابلة للاستبدال في الوادي. وفي حال نجاح الهجوم، يتم التخلي عن مجموعة شخصيات الرموز غير القابلة للاستبدال الأقل تصنيفاً، ويمكن اعتبار تلك الشخصية معرضة للإصابة، الأمر الذي يحول دون دخول هذه الشخصية المصابة مؤقتاً إلى الوادي المخبأ. يمكن تجميع ما يصل إلى خمس شخصيات للرموز غير القابلة للاستبدال في كل وادي مخبأ، وفي حال تم وضع أكثر من شخصيتين، عندئذ يتم منح مكافآت إضافية لهذا الطرف.
ستواصل "ويمايد" تطوير أنظمة جديدة ومثيرة لتوسيع لعبة MIRAGE، العالم المتعدد ضمن لعبة "إم آي آر 4"، وبناء منظومة اللعب داخل الألعاب.
المرجع
تقدم "ويمايد" منصة عالمية للتعاملات الرقمية "بلوك تشاين"، "ويميكس"، والتي يمكن بواسطتها تحويل الألعاب من مختلف الأنواع إلى ألعاب قائمة على تقنية التعاملات الرقمية "بلوك تشاين". يتم حالياً خدمة الكثير من الألعاب عبر "ويميكس"، وهي تهدف إلى خدمة 100 لعبة تعتمد العملة الرمزية "ويميكس توكن" باعتبارها عملتها الأساسية قبل نهاية العام 2022.
الرابط لصفحة "إم آي آر 4" Mirage على موقع "يوتيوب": https://www.youtube.com/watch?v=m05v3jHvL6E
تتوافر الصور/الوسائط المتعددة على الرابط الإلكتروني التالي: https://www.businesswire.com/news/home/52585669/en
إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.
Contacts
شركة "ويمايد" المحدودة (مدرجة في بورصة "كوسداك" تحت الرمز 112040: KOSDAQ)
يونغهيون لي، مدير العلاقات العامة
الرابط الثابت : https://www.aetoswire.com/ar/news/ويمايد-تكشف-النقاب-عن-لعبة-تجميع-مكافآت-جديدة-ضمن-لعبة-إم-آي-آر-4/ar
البريد الالكتروني: yeonghyun@wemade.com
Wemade Unveils New Staking Game for MIR4
Global NFT character staking game, MIRAGE, is introduced.
SEOUL, South Korea-Monday 28 February 2022 [ AETOS Wire ]
(BUSINESS WIRE) -- Wemade has unveiled a new NFT character staking game, MIRAGE, expanding the multiverse of its widely acclaimed MMORPG game, MIR4.
MIRAGE is a revolutionary staking game set in a parallel universe that exists separately from MIR4 while still interlinked with the ecosystem powered by Draco. Players can enlist their NFT characters from MIR4 on the web-based MIRAGE world in order to mine various Hidden Valley nodes for Darksteel and Septaria. MIRAGE offers a new approach to staking, built on the fundamentals of macromanagement through the gamification of character NFTs as playable assets, thereby expanding the range of economic activity within the MIR4 ecosystem.
Players will need a WEMIX Wallet account to participate and must enlist one or more NFT characters to their MIRAGE roster. Those without a MIR4 game account can still participate by logging in to the WEMIX Wallet.
Entrance to MIRAGE’s Hidden Valley requires Vigor, which can be obtained in exchange for Hydra, a game token in MIR4. There is a maximum number of characters that can be staked in each Hidden Valley, and, once a Hidden Valley is full, other players can attempt to ‘Assault’ the weakest character NFT in the valley. If the attack is successful, the staking of the lowest ranked NFT character is removed and that NFT character has a chance to become wounded, which temporarily restricts the wounded character from re-entering the Hidden Valley. Up to five NFT characters can be staked in each Hidden Valley, and if more than two characters are placed, then additional party bonuses will be given.
Wemade will continue to develop exciting new systems to expand MIRAGE, the multiverse of MIR4, and build the inter-games ecosystem.
Reference
Wemade offers a global blockchain platform, WEMIX, on which games of all genres can be transformed into blockchain games. Many games are currently being serviced on WEMIX, and it aims to service 100 games whose key currency is WEMIX Token prior to 2022 year-end.
MIR4 Mirage Youtube Link: https://www.youtube.com/watch?v=m05v3jHvL6E
Photos/Multimedia Gallery Available: https://www.businesswire.com/news/home/52585669/en
Contacts
Wemade Co., Ltd. (112040: KOSDAQ)
Yeonghyun Lee, PR Manager
yeonghyun@wemade.com
Permalink : https://www.aetoswire.com/news/wemade-unveils-new-staking-game-for-mir4/en
Glucophage® Is the First Oral Diabetes Treatment Approved in Europe for Use During Pregnancy
DARMSTADT, Germany-Monday 28 February 2022 [ AETOS Wire ]
- In a European worksharing procedure (WSP), Glucophage® was approved as the first oral anti-diabetic medication to be used safely from conception to birth.
- The approval was granted on the basis of Merck’s own safety cohort study CLUE1 and a large body of published evidence.
- This approval addresses a significant unmet medical need as the prevalence of hyperglycemia during pregnancy is rising worldwide, currently at one in six births (21.1 million).2
(BUSINESS WIRE) -- Merck, a leading science and technology company, today announced in a European worksharing procedure (WSP) an extension to the label for metformin products in the EU - Glucophage® (metformin hydrochloride [HCL] immediate release), Glucophage XR® (metformin HCL extended release) and Stagid® (metformin embonate immediate release) - for use throughout pregnancy.
Maria Rivas, SVP and Chief Medical Officer at Merck said, “During pregnancy and when wanting to become pregnant, good glycemic control is of utmost importance, as insufficient glycemic control leads to a three times higher risk of pregnancy loss than in normoglycemic women. The estimated risk of malformation is doubled. Until now, pregnant women were required to use insulin to control their blood sugar during this period. The label extension now opens a tablet alternative to women who are not able or wanting to use daily injections.”
In a European worksharing procedure (WSP), the variation for label extension was approved based on results from Merck’s register-based cohort safety study, investigating the follow up of children from over ~4.000 pregnancies with metformin1 for up to 11 years and extensive independent scientific publications, which all confirmed no increased risk of congenital abnormalities or feto/neonatal toxicity after exposure to metformin at the time of conception and throughout pregnancy.
Pregnancy and diabetes
The prevalence of type 2 diabetes is rising around the world.2 In 2021, 21.1 million births worldwide (16.7%) were affected by hyperglycemia.2 In Europe, 3-7% of all pregnant women develop gestational diabetes (GDM).3,4 Furthermore, 1% of all pregnancies are in women with pre-existing type 2 diabetes.5 To date, these conditions had to be managed with insulin when drugs were needed. Regarding the periconceptional phase, insulin-resistant polycystic ovary syndrome (PCOS), which affects 5-20% of all reproductive-aged women6,7, is associated with a 15-fold increase in infertility. The rate of early pregnancy loss is three times greater in PCOS pregnancies.
Metformin during pregnancy
The European Health authorities participating in the WSP weighed the benefit and risk of metformin use on both the mother and child. Their decision was informed by data investigating metformin in pre-gestational and gestational diabetes. Regarding the mother, metformin was comparable to insulin in reaching maternal blood sugar control and was better than insulin regarding pregnancy weight gain.8,9,10 Metformin use during pregnancy was associated with a lower risk of pregnancy-induced hypertension and preeclampsia.9,11,12 When used together with insulin for pregestational diabetes, metformin significantly lessened the amount of insulin required and lowered the risk of severe hypoglycemia.13,14
As metformin crosses the placenta,15,16,17 the safety of the unborn child had to be confirmed: Children exposed to metformin in utero may be born lighter than those exposed to insulin but are less in danger of a risky blood sugar dip directly after birth. So far, no long-term risks for the child later in life (e.g. on mental development and weight) have been confirmed.1
Metformin alone may sometimes not be enough to control blood glucose. In these cases, it is recommended for doctors to use metformin in combination with insulin21 or change to insulin.
=ENDS=
References
- Brand KMG, Saarelainen L, Sonajalg J, et al. Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study. BMJ Open Diab Res Care 2022;10:e002363
- IDF Diabetes Atlas, Tenth Edition 2021
- Behboudi-Gandevani S., Parajuli R., Vaismoradi M. A systematic review of the prevalence of gestational diabetes in Norway. [In Process] International Journal of Environmental Research and Public Health 2021 18:4 (1-12) Article Number 1423
- Wierzba W., Śliwczyński A., Karnafel W., Bojar I., Pinkas J. Gestational diabetes mellitus/hyperglycaemia during pregnancy in Poland in the years 2010-2012 based on the data from the National Health Fund. Ginekologia polska 2017 88:5 (244-248)
- Shub A., Lappas M.: Pregestational diabetes in pregnancy: Complications, management, surveillance, and mechanisms of disease—A review. Prenatal Diagnosis 2020 40:9 (1092-1098)
- National Health Statistics Reports Number 86, May 20, 2015. https://www.cdc.gov/nchs/data/nhsr/nhsr086.pdf
- McDonnell, Women’s Health 2017, Vol. 13(3) 89–97
- Tarry-Adkins PLoS Med 2020, 17(5): e1003126
- Guo, Journal of Diabetes Research 2019 Article Number 9804708
- Butalia Diabetic Medicine 2017 34:1 (27-36)
- Mateus Journal of Obstetrics and Gynecology 2020 222:1 Supplement (S691- S692)
- Cluver BMJ 2021;374:n2103
- Tarry-Adkins PLoS Med 2020, 17(5): e1003126
- Feig The Lancet Diabetes and Endocrinology 2020 8:10 (834-844)
- Charles Ther Drug Monit 28:67–72
- de Oliveira Baraldi. Clin Pharmacokinet 2012;51:743-9
- Ahmadimoghaddam Reprod Toxicol 2013;39:17-22
- Lee: DIABETICMedicine 2020. DOI: 10.1111/dme.14250
- Freinkel: Banting Lecture 1980: Of pregnancy and Progeny. Diabetes 1980: 1023- 35X
- Latif British Journal of Diabetes and Vascular Disease 2013 13:4 (178-182)
- Rowan New England Journal of Medicine 2008 358:19 (2003-2015)
About Glucophage®
Glucophage® (metformin hydrochloride) is a prescription-only medicine indicated for the treatment of type 2 diabetes mellitus, particularly when dietary management and exercise alone does not result in adequate glycaemic control. In adults, Glucophage® may be used as monotherapy or in combination with other oral anti-diabetic agents or with insulin. In children from 10 years old and adolescents, Glucophage® may be used as monotherapy or in combination with insulin. A reduction of diabetic complications has been shown in overweight type 2 diabetic adult patients treated with Glucophage® as first-line therapy after diet failure. The most commonly reported side effects with Glucophage® are gastro-intestinal disturbances that may occur during treatment initiation and resolve spontaneously in most cases. The Glucophage® product portfolio comprises: Glucophage® IR (immediate release) and Glucophage® XR (extended release) and Stagid® (metformin embonate immediate release).
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220227005209/en/
Contacts
falko.boehm@merckgroup.com
Phone: +49 151 145 497 87